Clinical trials: Patient With Colorectal Cancer
Advanced Colorectal Cancer
Regorafenib Monotherapy as Second-line Treatment of Patients With RAS-mutant Advanced Colorectal Cancer
The purpose of this study is to purpose of this study is to assess if regorafenib is active enough, in terms of 6-month progression-free rate, to warrant further comparative studies in patients with RAS-mutant advanced colorectal…
- Trial name
- STREAM (NCT02619435)
- Testing
- regorafenib
- Where
- 4 sites in Italy
- Volunteers
- 46 people
- Sponsor
- National Cancer Institute, Naples
Cancer
Massage Therapy in Treating the Symptoms of Patients With Locally Advanced or Metastatic Cancer
RATIONALE: Massage therapy may help relieve symptoms associated with cancer. It is not yet known which type of massage therapy is more effective in treating the symptoms of patients with cancer.
- Trial name
- NCT00253708
- Testing
- management of therapy complications, massage therapy, pain therapy
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- Beth Israel Deaconess Medical Center
Cancer
TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers
TTX-080-001 is a Phase 1, open label, dose escalation and dose expansion clinical study to determine the safety, tolerability, and recommended Phase 2 dose of TTX-080 monotherapy (HLA-G inhibitor) and in combination with either…
- Trial name
- NCT04485013
- Testing
- TTX-080, pembrolizumab, cetuximab
- Where
- 41 sites in United States
- Volunteers
- 240 people
- Sponsor
- Tizona Therapeutics, Inc
Advanced Colorectal Cancer
Effect of Curcumin on Dose Limiting Toxicity and Pharmacokinetics of Irinotecan in Patients With Solid Tumors
Curcumin is an extract of the tumeric root that has been shown to have anti-tumor properties in laboratory studies. Curcumin, and its parent spice, turmeric (curcuma longa), are the 4th most commonly purchased dietary supplement…
- Trial name
- NCT01859858
- Testing
- curcumin, Irinotecan
- Where
- 2 sites in United States
- Volunteers
- 23 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Colorectal Cancer
Combination Chemotherapy With or Without Cetuximab as First-Line Therapy in Treating Patients With Metastatic Colorectal Cancer
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00182715
- Testing
- cetuximab, capecitabine, fluorouracil
- Where
- 82 sites in Ireland, United Kingdom
- Volunteers
- 2,421 people
- Sponsor
- Velindre NHS Trust
Colorectal (Colon or Rectal) Cancer, Pelvic Malignancies
Utero-ovarian Transposition in Patients With Pelvic Malignancies Undergoing Whole Pelvic Radiotherapy
This study is designed as a Phase I clinical trial enrolling female patients aged 18-40 years who have been diagnosed with pelvic malignancies requiring whole pelvic external radiation therapy (WPXRT) and who express interest in…
- Conditions
- Colorectal (Colon or Rectal) Cancer, Pelvic Malignancies, Oncofertility
- Trial name
- UOT WPXRT (NCT07419490)
- Testing
- Uteroovarian transposition
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- University of South Florida
Colorectal Neoplasms, Enhanced Recovery After Surgery
Effects of Incomplete ERAS on Clinical Outcomes in Patients With Colorectal Cancer
Enhanced recovery after surgery (ERAS) has been reported to be associated with improved outcomes in many studies, most of which involve short-term effects.
- Trial name
- NCT05412355
- Testing
- ERAS protocol
- Where
- 2 sites in China
- Volunteers
- 1,000 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Colorectal Neoplasms, Neoplasm Metastasis
New Adjuvant Chemotherapy of Asymptomatic Resectable Primary Lesion With Unresectable Liver-limited Metastases
To evaluate the survival benefit of pre-operation chemotherapy of primary tumor tesection (PTR) compared upfront PTR for colorectal cancer (CRC) patients with an asymptomatic resectable primary tumor and synchronous unresectable…
- Conditions
- Colorectal Neoplasms, Neoplasm Metastasis, Liver Neoplasms, Chemotherapy; Maternal, Affecting Fetus
- Trial name
- NCT01307878
- Testing
- chemotherapy ± targeted therapy
- Where
- China
- Volunteers
- 320 people
- Sponsor
- Fudan University
Recurrent Colon Cancer, Recurrent Rectal Cancer
GTI-2040, Oxaliplatin, and Capecitabine in Treating Patients With Locally Advanced or Metastatic Colorectal Cancer or Other Solid Tumors
This phase I trial is studying the side effects and best dose of capecitabine when given together with GTI-2040 and oxaliplatin in treating patients with locally advanced or metastatic colorectal cancer or other solid tumors.
- Conditions
- Recurrent Colon Cancer, Recurrent Rectal Cancer, Stage IIIC Colon Cancer, Stage IIIC Rectal Cancer
- Trial name
- NCT00084643
- Testing
- GTI-2040, oxaliplatin, capecitabine
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- National Cancer Institute (NCI)
Colonic Neoplasms, Chemotherapy Effect
The Efficacy of JS001 Combined With Chemotherapy in Patients With Locally Advanced Colon Cancer
Colon cancer is one of the most lethal malignancies, and colorectal cancer ranks the fifth leading cause of tumor-related mortality in China. FOLFOX is the recommended adjuvant/ neoadjuvant treatment for advanced colon cancer.
- Trial name
- JSFOL (NCT03985891)
- Testing
- Anti-PD-1 Monoclonal Antibody JS001, Chemotherapy
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Xiangya Hospital of Central South University
Attenuated Familial Adenomatous Polyposis, Familial Adenomatous Polyposis
Erlotinib Hydrochloride in Reducing Duodenal Polyp Burden in Patients With Familial Adenomatous Polyposis at Risk of Developing Colon Cancer
This phase II trial studies the side effects of erlotinib hydrochloride and how well it works in reducing duodenal polyp burden in patients with familial adenomatous polyposis at risk of developing colon cancer.
- Trial name
- NCT02961374
- Testing
- Erlotinib, Erlotinib Hydrochloride
- Where
- 8 sites in United States, Puerto Rico
- Volunteers
- 46 people
- Sponsor
- National Cancer Institute (NCI)
Colorectal Cancer
Comparing Two Combination Chemotherapy Regimens in Treating Patients With Metastatic Colorectal Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00006468
- Testing
- FOLFOX regimen, fluorouracil, leucovorin calcium
- Where
- France
- Sponsor
- GERCOR - Multidisciplinary Oncology Cooperative Group
Familial Adenomatous Polyposis, FAP
Turmeric Supplementation on Polyp Number and Size in Patients With Familial Adenomatous Polyposis.
A Phase 2, randomized, double blind, placebo controlled trial for the effectivness of wholistic turmeric supplementation on polyp burden mong patients with Familial Adenomatouse Polyposis (FAP).
- Conditions
- Familial Adenomatous Polyposis, FAP, FAP Gene Mutation
- Trial name
- NCT03061591
- Testing
- Wholistic Turmeric capsules
- Volunteers
- 40 people
- Sponsor
- Tel-Aviv Sourasky Medical Center
Colorectal Cancer
Combination Chemotherapy and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00628810
- Testing
- bevacizumab, fluorouracil, irinotecan hydrochloride
- Where
- 32 sites in France
- Volunteers
- 86 people
- Sponsor
- Federation Francophone de Cancerologie Digestive
Colorectal Cancer Metastatic
Study of Aflibercept as Maintenance Therapy Following Induction With Aflibercept in Combination With XELOX, as First-Line Treatment for Metastatic Colorectal Cancer Patient
Primary Objectives: Study Part 1: To determine the recommended dose for the aflibercept, oxaliplatin and capecitabine (XELOX) combination to be used in the Part 2 of the study.
- Trial name
- AMOR (NCT01955629)
- Testing
- Aflibercept AVE0005, Oxaliplatin, Capecitabine
- Where
- 2 sites in Italy
- Volunteers
- 4 people
- Sponsor
- Sanofi
Colorectal Cancer
Split Dose Polyethylene Glycol (PEG) + Clear Fluids Versus Split Dose PEG + Low-Residue Diet
The objective of the study is to examine the effect of adding a strict low-residue lunch on the day before colonoscopy has on clinical efficacy and patient tolerability of bowel preparation, with patients receiving split-dose…
- Trial name
- BP (NCT01610895)
- Testing
- Split-dose PEG Based Lavage (2L + 2L) with Low-Fibre Lunch Dietary instructions, Split-dose PEG Based Lavage (2L + 2L) with Standard Dietary Instructions
- Where
- Canada
- Volunteers
- 345 people, healthy volunteers welcome
- Sponsor
- University of Calgary
Colorectal Cancer, Gastric Cancer
Samples Procurement for Colorectal Cancer, Gastric Cancer, and Non-malignant Disease
The purposes of this study are to collect and store samples including blood, normal and tumor tissue from patients with colorectal cancer or gastric cancer, to collect and store samples including blood and/or normal…
- Conditions
- Colorectal Cancer, Gastric Cancer, Inflammatory Bowel Diseases, Gastric Ulcer
- Trial name
- NCT03972956
- Testing
- No intervention will be given to patients.
- Where
- China
- Volunteers
- 1,000 people
- Sponsor
- Renmin Hospital of Wuhan University
Colorectal Neoplasms, Secondary Malignant Neoplasm of Liver
Iparomlimab/Tuvonralimab Combined With Bevacizumab and CAPEOX as Conversion Therapy for Colorectal Cancer Liver Metastasis
More than half of colorectal cancer (CRC) patients present with RAS mutations or right-sided primary tumors; however, objective response rates (ORRs) to bevacizumab combined with chemotherapy remain suboptimal.
- Trial name
- NCT07007728
- Testing
- Iparomlimab/Tuvonralimab, Bevacizumab + CAPEOX, Surgical resection ± ablation or stereotactic radiotherapy (if applicable)
- Where
- China
- Volunteers
- 54 people
- Sponsor
- Peking University Cancer Hospital & Institute
Colorectal Cancer, Metastatic Cancer
Combination Chemotherapy With or Without Cetuximab Before and After Surgery in Treating Patients With Resectable Liver Metastases Caused By Colorectal Cancer
RATIONALE: Drugs used in chemotherapy, such as oxaliplatin, fluorouracil, leucovorin, and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00482222
- Testing
- cetuximab, capecitabine, fluorouracil
- Where
- 22 sites in United Kingdom
- Volunteers
- 340 people
- Sponsor
- University of Southampton
Metastatic Colorectal Cancer, Circulating Tumor Cell
Circulating Tumor Cells in mCRC for Liver Resection
Resection of liver metastasis is potentially curative in patients with colorectal cancer bearing liver metastasis. However, early recurrence occurs in up to 30% in 3 months after liver resection.
- Trial name
- NCT03295591
- Testing
- Circulating tumor cell
- Where
- Hong Kong
- Volunteers
- 77 people
- Sponsor
- The University of Hong Kong
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.